IMNM

Business Context and Reporting Period

Immunome, Inc. (IMNM) is a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class therapies, including antibody-drug conjugates (ADCs) and radioligand therapies. The company reported for the quarterly period ended March 31, 2025. As of this date, Immunome had an accumulated deficit of $557.4 million and no product revenue, relying primarily on equity financing and collaboration agreements to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Significant Reduction in Net Loss: Net loss decreased by $87.9 million (68%) compared to Q1 2024. This improvement was primarily driven by the absence of $112.0 million in non-cash In-Process Research and Development (IPR&D) expenses recorded in Q1 2024 related to the acquisitions of assets from Zentalis and Ayala Pharmaceuticals.
• Revenue Growth: Collaboration revenue increased by $1.9 million, attributed to increased R&D activities allocated to the AbbVie collaboration agreement.
• Operating Expense Increase: Excluding the one-time IPR&D charges from the prior year, recurring operating expenses increased. Research and Development (R&D) expenses rose by $21.5 million to $36.9 million, driven by clinical trial activities for varegacestat and IM-1021. General and Administrative (G&A) expenses increased by $4.7 million due to higher personnel costs and share-based compensation.
• Capital Raise: In January 2025, the company completed a public offering of 22.3 million shares, generating net proceeds of $161.7 million, significantly bolstering its cash position.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects existing cash, cash equivalents, and marketable securities ($317.3 million) to fund operations for at least 12 months from the filing date. Additional financing will be required to support long-term objectives.
• Development Milestones:
  • Varegacestat: Phase 3 registrational trial enrollment completed in February 2024; topline data expected in the second half of 2025.
  • IM-1021: Phase 1 trial ongoing with first patient dosed in February 2025.
  • IM-3050: IND clearance received in April 2025; Phase 1 trial expected to initiate in the second half of 2025.
• Risks and Contingencies:
  • Regulatory Approval: No products have been approved; success depends on clinical trial outcomes and FDA approval.
  • Capital Requirements: The company has a history of losses and will require substantial additional funding. Failure to secure capital could force delays or termination of programs.
  • Third-Party Reliance: Reliance on third-party manufacturers and CROs introduces supply chain and execution risks.
  • Intellectual Property: Risks related to patent protection, enforcement, and potential infringement claims.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $317.3 million liquidity position against the projected burn rate, considering the acceleration of clinical trials for varegacestat and IM-1021.
• AbbVie Collaboration: Review the terms of the AbbVie agreement to understand the sustainability of the $2.9 million quarterly revenue stream and potential for future milestone payments.
• Phase 3 Data Timing: Monitor the timeline for the varegacestat Phase 3 topline data (expected H2 2025) as a critical value inflection point.
• Dilution Risk: Assess the impact of the recent 22.3 million share issuance and the remaining $180 million available under the ATM agreement on future shareholder dilution.
• IPR&D Accounting: Confirm that the significant reduction in Q1 2025 expenses is due to the absence of prior-year acquisition write-offs rather than a reduction in operational spending.